Observational analysis showed longer overall survival in endometrial cancer patients with microsatellite instability, indicating prognostic importance of MMR proteins.
Key Points
Overall survival was significantly longer in the microsatellite instable group, averaging 52 months compared to 31 months in microsatellite stable patients.
Eighty-three percent of endometrial cancer patients were classified as microsatellite stable based on mismatch repair protein expression.
Immunohistochemical analysis assessed key MMR proteins, revealing associations with clinical and pathological outcomes.
Highlights the value of microsatellite instability as a biomarker for guiding personalized treatment strategies.